$ACRV

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 acrv-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan Adopted by the Board of Directors: May 20, 2026 Approved by the Stockholders: June 17, 2026 1. General. (a) Successor to and Continuation of Prior Pla

Acrivon Therapeutics, Inc.'s Chief Operating Officer, Eric Devroe, had 613 shares of Common Stock withheld on May 14, 2026, to cover tax obligations related to restricted stock unit vesting. The shares were valued at $1.92 each for this administrative tax-withholding disposition, which is not an open-market sale. Following this transaction, Devroe directly holds 73,972 Common Stock shares, maintaining his equity position after satisfying the required tax liability.

This article analyzes the historical performance of investing $1,000 in Acrivon Therapeutics, Inc. (ACRV) over one, five, and ten years, showing significant losses and underperformance compared to the S&P 500. It also provides a detailed overview of Acrivon Therapeutics, explaining its proprietary Generative Phosphoproteomics AP3 platform, its lead clinical candidates ACR-368 and ACR-2316, and its preclinical pipeline. The company is a clinical-stage biopharmaceutical firm focused on precision oncology using AI-driven drug discovery and companion diagnostics.

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development ...

WATERTOWN, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Acrivon Therapeutics, Inc. ( "Acrivon" or "Acrivon Therapeutics" ) ( Nasdaq: ACRV ) , a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 ( Acrivon ...

Shares of Robinhood Markets, Inc. HOOD rose sharply in pre-market trading. S&P Dow Jones Indices announced a sweeping update to its benchmarks late Friday, unveiling new additions to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600. Robinhood will replace Caesars Entertainment Inc.

Acrivon Therapeutics ( NASDAQ:ACRV ) , a clinical-stage biotech developing precision oncology medicines, released its second quarter 2025 results on August 13, 2025. The report showed a GAAP net loss per share of $ ( 0.55 ) , beating estimates by $0.02 ( GAAP EPS: -$0.55 vs. estimate: -$0.57 ) .

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types ...

Acrivon Therapeutics, Inc. (ACRV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's ...